Sjogren’s syndrome: evolving therapies

Abstract

Sjogren’s syndrome (keratoconjunctivis sicca) is a relatively common disorder with incidence of ∼ 0.5% of adult women. It has both local (ocular and oral) features as well as systemic manifestations. There has been recent FDA approval of agents to stimulate salivation (pilocarpine and cevimeline) and studies are in progress to determine their role in the treatment of dry eye. New therapies are in clinical trials for ocular manifestations with the most interest focused on topical cyclosporin A and purinogenic receptor agonists. In oral therapy, topical human interferon has reported encouraging results in short-term studies. However, the high placebo response (probably reflecting the beneficial response of mechanical stimulation of the buccal mucosa by the lozenge) and the response to much cheaper therapies (such as acid maltose lozenges) may offer safer and cheaper alternatives. For systemic disease, there is interest in tumour necrosis factor inhibitors. However, the cost-effectiveness and safety of biological agents needs longer term follow up, as they appear much less dramatic in their effect on systemic lupus erythematosus or Sjogren’s syndrome than in rheumatoid arthritis.

• arthritis
• autoimmune
• dry eye
• dry mouth
• keratoconjunctivis sicca
• Sjogren's syndrome
• xerostomia
• xerothalmia